AACE president Dr Sethu Reddy highlights evidence-based updates, including selection of diabetes medication based on comorbidities and new agents to treat DKD and elevated lipids.
All News

Semaglutide yields "amazing" weight loss in adolescents, phenotype-tailored lifestyle approach leads to greater weight loss vs standard methods, and more.

Weight management in children and adolescents with obesity requires unique sensitivity to the physical and emotional needs of these vulnerable pediatric patients.

Your daily dose of clinical news you may have missed.

AHA 2022: Study authors say more research is needed to investigate the impact of targeting social determinants of health to improve cardiometabolic risk and mortality in pregnant women.

Sotagliflozin Cuts Risk by >50% for Heart Failure Readmission, CV Death in Phase 3 SOLOIST-WHF Trial
In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.
The man, in his 30s, has seen 2 specialists, received 2 diagnoses, and is now in the ED for persistent pain that is worsened by eye motion. Can you dx?
.jpg?w=350&fit=crop&auto=format)
Black women seeking fertility care were less likely to report getting COVID-19 vaccine and were unsatisfied with how major health care systems handled the pandemic.

Your daily dose of clinical news you may have missed.
The novel approach to targeted obesity treatment could improve weight loss outcomes, suggest findings from ObesityWeek® 2022.

I have admitted infants to the hospital every winter for 40 years, yet I still don't have good answers for anxious parents watching their child struggling to breathe.

Your daily dose of clinical news you may have missed.

Study authors saw a positive dose-response relationship driven by hemorrhagic stroke in young adults who were moderate-to-heavy drinkers in their 20s and 30s.

The 2022 guidance covers acute, subacute, and chronic pain and replaces the 2016 guidelines.

The Nerivio REM device demonstrated a statistically significant reduction in migraine days/month vs a placebo device in both chronic and episodic migraine.

Empagliflozin Reduced Risk of Renal Disease Progression, CV Death Across CKD Spectrum in EMPA-KIDNEY
Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.
Reddy talks about the value of A1c vs results of an OGTT for T2D diagnosis, about glycemic targets and patient safety, hyperglycemia during pregnancy, and more in our interview.

Your daily dose of clinical news you may have missed.

An OTC progestin only pill could potentially reduce the number of annual unintended pregnancies in the US by tens of thousands, a novel modeling study reveals.

AHA 2022: Chronic users of either e-cigarettes or traditional cigarettes had acute changes in cardiovascular function and performed worse on exercise stress testing than never users in new study.
